Primary Peritoneal Carcinoma Active Not Recruiting Phase 3 Trials for Mirvetuximab Soravtansine (DB12489)

IndicationStatusPhase
DBCOND0028874 (Primary Peritoneal Carcinoma)Active Not Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02631876PH3 Study of Mirvetuximab Soravtansine vs Investigator's Choice of Chemotherapy in Women With FRa+ Adv. EOC, Primary Peritoneal or Fallopian Tube CancerTreatment